HLSQ Tessera Defense & Homeland Security Inc.
NYSE · SEC CIK 1739174 · EDGAR
- Bought, last 12 months
- $0 0 purchases by 0 insiders
- Sold, last 12 months
- $8.25M 2 sales by 1 insiders
- Filings on record
- 93 since 2021-07-28, latest 2026-03-18
BoughtSold
Most active insiders, 12 months
| Insider | Title | Bought | Sold |
|---|---|---|---|
| Yeganeh Reuven | Dir, 10% | — | $8.25M |
Transactions 37
Purchase Sale Sale after option exercise All abbreviations
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| DMI | 2026-03-18 | 2026-03-16+ | HLSQ | Yeganeh Reuven | Dir, 10% | C - Cnv Deriv | $2.00 | +980.0K | 450.0K | New | +$1.96M |
| DMI | 2026-03-18 | 2026-03-16+ | HLSQ | Yeganeh Reuven | Dir, 10% | S - Sale | $5.00 | -980.0K | 0 | -100% | -$4.90M |
| DMI | 2026-03-13 | 2026-03-12+ | HLSQ | Yeganeh Reuven | Dir, 10% | S - Sale | $5.00 | -670.0K | 0 | -100% | -$3.35M |
| DMI | 2026-03-13 | 2026-03-11+ | HLSQ | Yeganeh Reuven | Dir, 10% | C - Cnv Deriv | $2.00 | +670.0K | 30.0K | New | +$1.34M |
| DA | 2025-04-21 | 2025-04-14 | HLSQ | Solomon Jonathan Eitan | CEO, Dir | A - Grant | $0.00 | +126.7K | 126.7K | New | $0 |
| DA | 2025-04-21 | 2025-04-14 | HLSQ | Bassan Merav | Chief Development Off | A - Grant | $0.00 | +79.6K | 79.6K | New | $0 |
| DA | 2025-04-21 | 2025-04-14 | HLSQ | Wolfson Marina | CFO | A - Grant | $0.00 | +68.5K | 68.5K | New | $0 |
| D | 2025-04-18 | 2025-04-14 | HLSQ | Bassan Merav | Chief Development Off | A - Grant | $0.00 | +79.6K | 79.6K | New | $0 |
| D | 2025-04-18 | 2025-04-14 | HLSQ | Wolfson Marina | CFO | A - Grant | $0.00 | +68.5K | 68.5K | New | $0 |
| D | 2025-04-18 | 2025-04-14 | HLSQ | Solomon Jonathan Eitan | CEO, Dir | A - Grant | $0.00 | +126.7K | 126.7K | New | $0 |
| DMI | 2025-03-03 | 2025-02-27 | HLSQ | DEERFIELD MANAGEMENT COMPANY, L.P. (SERIES C) | Dir, *Dir by Deputization | M - OptEx | $0.93 | +706.5K | 1.25M | +131% | +$657.0K |
| 2024-09-18 | 2024-09-16 | HLSQ | Oron Assaf | Chief Business Off | A - Grant | $0.00 | +25.8K | 25.8K | New | $0 | |
| 2024-09-18 | 2024-09-16 | HLSQ | Bassan Merav | Chief Development Off | A - Grant | $0.00 | +31.7K | 31.7K | New | $0 | |
| 2024-09-18 | 2024-09-16 | HLSQ | Solomon Jonathan Eitan | CEO, Dir | A - Grant | $0.00 | +50.6K | 53.1K | +2,022% | $0 | |
| DMI | 2024-07-17 | 2024-07-15 | HLSQ | Deerfield Mgmt HIF, L.P. | Dir, *Dir by Deputization | M - OptEx | — | +11.77M | 8.94M | New | — |
| DI | 2024-05-20 | 2024-05-15 | HLSQ | GORDON CARL L | 10% | S - Sale+OE | $0.38 | -24.3K | 13.77M | -0.2% | -$9,251 |
| DI | 2024-05-20 | 2024-05-15 | HLSQ | GORDON CARL L | 10% | X - OptEx | $0.24 | +9.28M | 13.80M | +205% | +$2.23M |
| D | 2024-05-17 | 2024-05-15 | HLSQ | Cystic Fibrosis Foundation | 10% | X - OptEx | $0.00 | +4.78M | 9.33M | +105% | $0 |
| DMI | 2024-03-19 | 2024-03-15 | HLSQ | Deerfield Mgmt HIF, L.P. | Dir, 10%, *Dir by Deputization | A - Grant | — | +6.11M | 3.06M | New | — |
| M | 2023-12-01 | 2023-11-29 | HLSQ | Oron Assaf | Chief Business Off | S - Sale | $0.3731 | -10.9K | 0 | -100% | -$4,072 |
| 2023-05-24 | 2023-05-22 | HLSQ | Oron Assaf | Chief Business Off | P - Purchase | $0.27 | +3,192 | 10.9K | +41% | +$861.84 | |
| M | 2023-05-22 | 2023-05-18+ | HLSQ | Oron Assaf | Chief Business Off | P - Purchase | $0.2784 | +7,722 | 1,201 | New | +$2,150 |
| DI | 2023-03-17 | 2023-02-27 | HLSQ | OrbiMed Israel GP Ltd. | 10% | P - Purchase | $0.25 | +348.0K | 3.16M | +12% | +$87.0K |
| MI | 2022-11-14 | 2022-08-10+ | HLSQ | Ugwumba Chidozie | Exit Form 4 - former 10% owner | S - Sale | $0.6399 | -288.6K | 3.58M | -7% | -$184.7K |
| MI | 2022-11-14 | 2022-09-16+ | HLSQ | Ugwumba Chidozie | Exit Form 4 - former 10% owner | S - Sale | $0.3874 | -277.2K | 3.27M | -8% | -$107.4K |
| MI | 2022-11-14 | 2022-10-17+ | HLSQ | Ugwumba Chidozie | Exit Form 4 - former 10% owner | S - Sale | $0.3571 | -75.0K | 3.02M | -2% | -$26.8K |
| DI | 2022-02-14 | 2021-12-31 | HLSQ | Walton Thomas Layton | 10% | J - Other | $0.00 | -3.64M | 0 | -100% | $0 |
| DA | 2021-08-17 | 2021-07-26 | HLSQ | GROSSMAN JONAS | Dir | P - Purchase | — | +37.5K | 372.7K | +11% | — |
| DI | 2021-07-30 | 2021-07-28 | HLSQ | OrbiMed Israel BioFund GP Limited Partnership | 10% | P - Purchase | — | +500.0K | 2.81M | +22% | — |
| D | 2021-07-30 | 2021-07-28 | HLSQ | Moses Alan Charles | Dir | P - Purchase | $4.00 | +5,000 | 5,000 | New | +$20.0K |
| D | 2021-07-30 | 2021-07-28 | HLSQ | SEKHRI PAUL J | Dir | P - Purchase | $4.00 | +12.5K | 12.5K | New | +$50.0K |
| DI | 2021-07-30 | 2021-07-28 | HLSQ | Greig Russell | Dir | P - Purchase | $4.00 | +3,750 | 3,750 | New | +$15.0K |
| D | 2021-07-30 | 2021-07-28 | HLSQ | Solomon Jonathan Eitan | CEO, Dir | P - Purchase | $4.00 | +25.0K | 25.0K | New | +$100.0K |
| D | 2021-07-30 | 2021-07-28 | HLSQ | Sullivan Lynne Marie | Dir | P - Purchase | $4.00 | +12.5K | 12.5K | New | +$50.0K |
| D | 2021-07-30 | 2021-07-28 | HLSQ | Wolfson Marina | SVP of Fin, Ops | P - Purchase | $4.00 | +3,750 | 3,750 | New | +$15.0K |
| D | 2021-07-28 | 2021-07-26 | HLSQ | Amusa Gbolahan | Dir | P - Purchase | — | +25.0K | 262.9K | +11% | — |
| D | 2021-07-28 | 2021-07-26 | HLSQ | GROSSMAN JONAS | Dir | P - Purchase | — | +37.5K | 372.2K | +11% | — |